HC Wainwright & Co. Reiterates Buy on Ikena Oncology, Maintains $11 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Andres Maldonado has reiterated a Buy rating on Ikena Oncology (NASDAQ:IKNA) and maintained an $11 price target.
March 19, 2024 | 11:05 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. analyst Andres Maldonado reiterated a Buy rating on Ikena Oncology with an $11 price target.
The reiteration of a Buy rating and maintenance of an $11 price target by a reputable analyst could positively influence investor sentiment towards IKNA, potentially driving its stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100